175 related articles for article (PubMed ID: 33195345)
21. Pediatric IgA Nephropathy in Europe.
Coppo R
Kidney Dis (Basel); 2019 Jun; 5(3):182-188. PubMed ID: 31259180
[TBL] [Abstract][Full Text] [Related]
22. Pro: STOP immunosuppression in IgA nephropathy?
Pozzi C
Nephrol Dial Transplant; 2016 Nov; 31(11):1766-1770. PubMed ID: 27515694
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease.
Li XW; Liang SS; Le WB; Cheng SQ; Zeng CH; Wang JQ; Liu ZH
J Nephrol; 2016 Aug; 29(4):567-73. PubMed ID: 26537358
[TBL] [Abstract][Full Text] [Related]
24. Treatment of IgA nephropathy with renal insufficiency.
Pozzi C; Sarcina C; Ferrario F
J Nephrol; 2016 Aug; 29(4):551-8. PubMed ID: 26743078
[TBL] [Abstract][Full Text] [Related]
25. Prognosis of IgA Nephropathy with Stage 3b-5 CKD.
Wu Z; Li H; Liu Y; Wang F; Xing Y; Li W; Jia J; Yan T
Kidney Blood Press Res; 2024 Apr; ():. PubMed ID: 38565098
[TBL] [Abstract][Full Text] [Related]
26. Immunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group.
Oruc A; Sumnu A; Turkmen A; Basturk T; Cebeci E; Turgutalp K; Cetinkaya H; Uzerk Kibar M; Seyahi N; Tatar E; Ergul M; Derici Ü; Aylı MD; Pınar M; Bakar B; Kazancıoglu R; Yıldız A; Dirim AB; Yılmaz Z; Turkmen K; Tunca O; Koc M; Kutlay S; Micozkadıoglu H; Azak A; Boztepe B; Ustundag S; Şafak Ozturk S; Unsal A; Karadag S; Sahin G; Yenigun EC; Eren N; Gullulu M; Gursu M; Ozturk S
Ren Fail; 2024 Dec; 46(1):2341787. PubMed ID: 38637275
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy.
Li Y; Xiong Y; Huang T; Liu X; Xu G
BMC Nephrol; 2021 Nov; 22(1):364. PubMed ID: 34736419
[TBL] [Abstract][Full Text] [Related]
28. Corticosteroids pulse therapy and oral corticosteroids therapy for IgA nephropathy patients with advanced chronic kidney disease: results of a multicenter, large-scale, long-term observational cohort study.
Tsunoda R; Usui J; Hoshino J; Fujii T; Suzuki S; Takaichi K; Ubara Y; Yamagata K
BMC Nephrol; 2018 Sep; 19(1):222. PubMed ID: 30189860
[TBL] [Abstract][Full Text] [Related]
29. Corticosteroid in IgA nephropathy with moderate proteinuria: A retrospective cohort study.
Wang Y; Yu J; Jiang Y; Li J; Yimamuyushan A; Xia X; Fan L; Huang F; Chen W; Liu Q
Nephrology (Carlton); 2024 May; 29(5):268-277. PubMed ID: 38186010
[TBL] [Abstract][Full Text] [Related]
30. Long-term kidney survival analyses in IgA nephropathy patients under steroids therapy: a case control study.
Yuan Y; Wang Q; Ni Z; Che X; Cao L; Shao X; Zhang M; Xie Y; Qi C; Zhou W; Tian L; Mou S
J Transl Med; 2015 Jun; 13():186. PubMed ID: 26048044
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of sequential immunosuppressive treatment for severe IgA nephropathy: A retrospective study.
Luo MN; Pan Q; Ye T; Li S; Yang L; Liu HF; Xu Y
Front Pharmacol; 2023; 14():1093442. PubMed ID: 36998610
[No Abstract] [Full Text] [Related]
32. Immunosuppressants or corticosteroids compared with supportive therapy: a systematic review and meta-analysis on the efficacy and safety for IgA nephropathy treatment.
Feng Q; Xiong Y; Wang J; Feng L
Ann Transl Med; 2022 Mar; 10(6):355. PubMed ID: 35433980
[TBL] [Abstract][Full Text] [Related]
33. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population.
Le W; Liang S; Hu Y; Deng K; Bao H; Zeng C; Liu Z
Nephrol Dial Transplant; 2012 Apr; 27(4):1479-85. PubMed ID: 21965586
[TBL] [Abstract][Full Text] [Related]
34. Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study.
Bagchi S; Mani K; Swamy A; Barwad A; Singh G; Bhowmik D; Agarwal SK
Kidney Int Rep; 2021 Jun; 6(6):1661-1668. PubMed ID: 34169207
[TBL] [Abstract][Full Text] [Related]
35. IgA nephropathy: prognostic classification of end-stage renal failure. L'Association des Néphrologues de l'Est.
Frimat L; Briançon S; Hestin D; Aymard B; Renoult E; Huu TC; Kessler M
Nephrol Dial Transplant; 1997 Dec; 12(12):2569-75. PubMed ID: 9430853
[TBL] [Abstract][Full Text] [Related]
36. Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children.
Kang Z; Li Z; Duan C; Wu T; Xun M; Ding Y; Zhang Y; Zhang L; Yin Y
Pediatr Nephrol; 2015 Jul; 30(7):1121-9. PubMed ID: 25773534
[TBL] [Abstract][Full Text] [Related]
37. Arterial-Arteriolar Sclerosis Is Independently Associated With Poor Renal Outcome in IgA Nephropathy Patients.
Dong L; Tan J; Li F; Wang S; Jiang Z; Qin A; Zhong Z; Zhou X; Tang Y; Qin W
Front Med (Lausanne); 2021; 8():761897. PubMed ID: 34869465
[No Abstract] [Full Text] [Related]
38. Oral glucocorticoids with intravenous cyclophosphamide or oral glucocorticoids alone in the treatment of IgA nephropathy present with nephrotic syndrome and mesangioproliferative glomerulonephritis.
Du W; Chen Z; Fang Z; Li J; Weng Q; Zheng Q; Xie L; Yu H; Gu X; Shi H; Wang Z; Ren H; Wang W; Ouyang Y; Xie J
Clin Kidney J; 2023 Dec; 16(12):2567-2577. PubMed ID: 38046021
[TBL] [Abstract][Full Text] [Related]
39. Pregnancy and Kidney Outcomes in Patients With IgA Nephropathy: A Cohort Study.
Su X; Lv J; Liu Y; Wang J; Ma X; Shi S; Liu L; Zhang H
Am J Kidney Dis; 2017 Aug; 70(2):262-269. PubMed ID: 28320554
[TBL] [Abstract][Full Text] [Related]
40. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.
Rauen T; Fitzner C; Eitner F; Sommerer C; Zeier M; Otte B; Panzer U; Peters H; Benck U; Mertens PR; Kuhlmann U; Witzke O; Gross O; Vielhauer V; Mann JFE; Hilgers RD; Floege J
J Am Soc Nephrol; 2018 Jan; 29(1):317-325. PubMed ID: 29042456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
